Nanostructured Interface Loaded with Chimeric Enzymes for Fluorimetric Quantification of Cyclosporine A and FK506

Anal Chem. 2022 May 24;94(20):7303-7310. doi: 10.1021/acs.analchem.2c00650. Epub 2022 May 11.

Abstract

Advances in protein engineering resulted in increased efforts to create protein biosensors that can replace instrumentation-heavy analytical and diagnostic methods. Sensitivity, amenability to multiplexing, and manufacturability remain to be among the key issues preventing broad utilization of protein biosensors. Here, we attempt to address these by constructing arrays utilizing protein biosensors based on the artificial allosteric variant of PQQ-glucose dehydrogenase (GDH). We demonstrated that the silica nanoparticle-immobilized GDH protein could be deposited on fiberglass sheets without loss of activity. The particle-associated GDH activity could be monitored using changes in the fluorescence of the commonly used electron mediator phenazine methosulfate. The constructed biosensor arrays of macrocyclic immunosuppressant drugs cyclosporine A and FK-506 displayed very low background and a remarkable dynamic range exceeding 300-fold that resulted in a limit of detection of 2 pM for both analytes. This enabled us to quantify both drugs in human blood, serum, urine, and saliva. The arrays could be stored in dry form and quantitatively imaged using a smartphone camera, demonstrating the method's suitability for field and point-of-care applications. The developed approach provides a generalizable platform for biosensor array development that is compatible with inexpensive and potentially scalable manufacturing.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biosensing Techniques* / methods
  • Cyclosporine
  • Glucose 1-Dehydrogenase / metabolism
  • Humans
  • Recombinant Fusion Proteins
  • Tacrolimus*

Substances

  • Recombinant Fusion Proteins
  • Cyclosporine
  • Glucose 1-Dehydrogenase
  • Tacrolimus